Catalog Products » GFRA3, His, Mouse
Manual
Manual
COAs

GFRA3, His, Mouse

GDNF (glial-cell-line derived neurotrophic factor) is a potent neurotrophic factor for dopaminergic neurons. Neuropsychiatric diseases and their treatments are associated with alterations in the levels of both GDNF and its receptor family (GDNF family receptor alpha or GFRA). GFRA1, GFRA2 and GFRA3 are located in chromosomal regions with suggestive linkage to schizophrenia.
$370.00
Z06140-100

Ask us a question
Product Introduction
Species Mouse
Protein Construction
GFRA3 (Asn29-Arg379)_x000D_
Accession # O35118		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 40.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 47-52 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

GFRA3, His, Mouse

Immobilized Mouse ARTN, hFc Tag at 5 μg /ml (100 μl/well) on the plate. Dose response curve for GFRA3, His, Mouse, His Tag with the EC50 of 34.8ng/ml determined by ELISA. »

GFRA3, His, Mouse

The purity of GFRA3, His, Mouse is greater than 95% as determined by SEC-HPLC. »

GFRA3, His, Mouse

GFRA3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background GDNF (glial-cell-line derived neurotrophic factor) is a potent neurotrophic factor for dopaminergic neurons. Neuropsychiatric diseases and their treatments are associated with alterations in the levels of both GDNF and its receptor family (GDNF family receptor alpha or GFRA). GFRA1, GFRA2 and GFRA3 are located in chromosomal regions with suggestive linkage to schizophrenia.
Synonyms GDNFR-alpha-3; GFR-alpha-3; GFRA3; GFR alpha3; GPI-linked receptor
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.